Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Simultaneous PET/MR Imaging of Brain Glucose and Oxygen Metabolism to Assess Energy Deficits Related to Alzheimer's Disease and the Response to Intervention

Award Number: R01NS131235
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/26/2024
PERIOD OF PERFORMANCE END DATE: 02/29/2028

Group Awards By:

View Award Description

Simultaneous PET/MR Imaging of Brain Glucose and Oxygen Metabolism to Assess Energy Deficits Related to Alzheimer's Disease and the Response to Intervention - PROJECT SUMMARY There are now close to six million people in the Unites States living with Alzheimer’s disease and related de- mentias (ADRD) and this number is only expected to grow as the population continues to age. The current lack of effective treatments for ADRD speaks to the need to better understand the multiple pathophysiological factors that contribute to these complex diseases. There is growing evidence that age-related metabolic dysfunction plays a role in the Alzheimer’s etiology. The link between vascular risk factors and AD is explained in part by insufficient nutrient delivery to match the high energy demands of the brain and less efficient energy production as the brain ages. The concept of a “brain energy gap” has led to treatments aimed at enhancing energy pro- duction and cognitive performance, notably, ketogenic dietary supplements. These have been shown to increase cerebral ketone metabolism in AD patients, suggesting improved aerobic metabolism. However, this hypothesis has not been tested given the complexity of imaging oxygen and glucose metabolism. Positron emission tomog- raphy (PET) is the current standard, but the procedure requires 18F-fluorodeoxglucose (FDG) to measure glucose metabolism, 3 15O-tracers to measure oxygen metabolism and blood flow, and arterial sampling for quantification. We hypothesize that cerebral oxygen and glucose metabolism can be imaged noninvasively within a single session using hybrid PET/magnetic resonance imaging (PET/MRI). Our team has developed a robust quantitative blood oxygenation level dependent contrast (qBOLD) method of imaging oxygen extraction, which can be combined with MRI-based perfusion (arterial spin labeling, ASL) to map cerebral oxygen metabolism. In tandem, we have developed a PET approach for quantifying glucose metabolism that does not require arterial catheterization. Combining these methods on a PET/MR scanner provides the ability to image oxygen and glu- cose metabolism simultaneously and non-invasively, thereby reducing scan time, radiation dose and patient discomfort. As part of the proposed research, we will validate our qBOLD/ASL method for imaging oxygen me- tabolism by comparison to 15O-PET. Conducting these studies on a PET/MR system will ensure the PET and MRI measurements are collected under the same physiological state. The MRI oximetry method will be combined with FDG PET to investigate the effects of a ketogenic supplement on oxygen and glucose metabolism in AD patients. The outcomes of this project will include validating an MRI-based method for imaging oxygen metabo- lism and demonstrating how it can be combined with FDG PET to evaluate a treatment that targets the brain energy gap associated with AD. Replacing 15O-PET by MRI oximetry would greatly enhance the feasibility of imaging substrate (i.e. glucose) and total energy metabolism (i.e. oxygen) considering how few PET sites with 15O capabilities remain, while FDG is the most used tracer. The longer-term goals are to provide non-invasive, neuro-imaging tools for studying individuals with ADRD and evaluate effectiveness of emerging drugs.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $482,807 )
2026	2026	TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE	3451 WALNUT ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	5/5/2026	NON-COMPETING CONTINUATION	$482,807
														Subtotal = $482,807

Issue Date FY: 2025 ( Subtotal = $432,482 )
2025	2025	TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE	3451 WALNUT ST STE 440A	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	2/20/2025	NON-COMPETING CONTINUATION	$432,482
														Subtotal = $432,482

Issue Date FY: 2024 ( Subtotal = $492,324 )
2024	2024	TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE	3451 WALNUT ST STE 440A	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	3/25/2024	NEW	$492,324
														Subtotal = $492,324

Grand Total All Awards = $1,407,613

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Simultaneous PET/MR Imaging of Brain Glucose and Oxygen Metabolism to Assess Energy Deficits Related to Alzheimer's Disease and the Response to Intervention

Award Number: R01NS131235

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/26/2024

PERIOD OF PERFORMANCE END DATE: 02/29/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer